RWD161 Therapeutic Drug Monitoring (TDM) of Infliximab Is Associated with Lower Biologic Switch Expenditures Compared to No-TDM Cohort of IBD Patients Based on 12 to 48-Month Real-World Outcomes from a US Community GI Practice
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.1815
https://www.valueinhealthjournal.com/article/S1098-3015(24)01930-2/fulltext
Section Title :
Section Order :
11464
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)01930-2&doi=10.1016/j.jval.2024.03.1815